Recommendations and guidelines for the diagnosis and treatment of Fabry nephropathy in adults

Nature Clinical Practice Nephrology

Volumn 4, Issue 6, 2008, Pages 327-336

  Ortiz, Alberto ^a   Oliveira, João P ^b   Wanner, Christoph ^c   Brenner, Barry M ^d   Waldek, Stephen ^e   Warnock, David G ^f  

^a UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^b HOSPITAL DE SÃO JOÃO   (Portugal)

^c UNIVERSITY OF WÜRZBURG   (Germany)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

^e SALFORD ROYAL NHS FOUNDATION TRUST   (United Kingdom)

^f University of Alabama at Birmingham   (United States)

Author keywords

Agalsidase; Enzyme replacement therapy; Fabry nephropathy; Glomerular filtration rate; Proteinuria

Indexed keywords

AGALSIDASE ALFA; AGALSIDASE BETA; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHISTAMINIC AGENT; ANTIPYRETIC AGENT; CORTICOSTEROID; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; PLACEBO;

CLINICAL FEATURE; CLINICAL TRIAL; DISEASE COURSE; DRUG DOSE INCREASE; ENZYME REPLACEMENT; FABRY DISEASE; FEVER; GLOMERULUS FILTRATION RATE; HUMAN; HYPOTENSION; KIDNEY BIOPSY; KIDNEY DISEASE; KIDNEY FUNCTION; LOW DRUG DOSE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROTEINURIA; RECOMMENDED DRUG DOSE; REVIEW; RIGOR; SEX DIFFERENCE; URTICARIA;

ADULT; ALPHA-GALACTOSIDASE; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BIOPSY, NEEDLE; CREATININE; DISEASE PROGRESSION; FABRY DISEASE; FEMALE; FOLLOW-UP STUDIES; GLOMERULAR FILTRATION RATE; HUMANS; IMMUNOHISTOCHEMISTRY; INCIDENCE; MALE; MIDDLE AGED; PRACTICE GUIDELINES AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SEX DISTRIBUTION; TREATMENT OUTCOME; TRIHEXOSYLCERAMIDES;

EID: 44449115633     PISSN: 17458323     EISSN: 17458331     Source Type: Journal    
DOI: 10.1038/ncpneph0806     Document Type: Review

References (58)

1. Desnick R et al. (2001) Alpha-Galactosidase A deficiency: Fabry disease. In The Metabolic Bases of Inherited Disease, edn 8, 3733-3774 (Eds Scriver C et al.) New York: McGraw-Hill
2. Eng CM et al. (2007) Fabry disease: baseline medical characteristics of a cohort of 1765 males and females in the Fabry Registry. J Inherit Metab Dis 30: 184-192
3. Mehta A et al. (2004) Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey. Eur J Clin Invest 34: 236-242
4. Wang RY et al. (2007) Heterozygous Fabry women are not just carriers, but have a significant burden of disease and impaired quality of life. Genet Med 9: 34-45
5. Wilcox WR et al. (2008) Females with X-linked Fabry disease frequently have significant organ involvement. Mol Genet Metab 93: 112-128
6. Branton MH et al. (2002) Natural history of Fabry renal disease: influence of alpha-galactosidase A activity and genetic mutations on clinical course. Medicine (Baltimore) 81: 122-138
7. Eng CM et al. (2001) A phase 1/2 clinical trial of enzyme replacement in Fabry disease: pharmacokinetic, substrate clearance, and safety studies. Am J Hum Genet 68: 711-722
8. Wilcox WR et al. (2004) Long-term safety and efficacy of enzyme replacement therapy for Fabry disease. Am J Hum Genet 75: 65-74
9. Banikazemi M et al. (2007) Agalsidase-beta therapy for advanced Fabry disease: a randomized trial. Ann Intern Med 146: 77-86
10. Germain D et al. (2007) Sustained, long-term renal stabilization after 54 months of agalsidase beta therapy in patients with Fabry disease. J Am Soc Nephrol 18: 1547-1557
11. Desnick RJ (2004) Enzyme replacement therapy for Fabry disease: lessons from two alpha-galactosidase A orphan products and one FDA approval. Expert Opin Biol Ther 4: 1167-1176
12. Schiffmann R et al. (2001) Enzyme replacement therapy in Fabry disease: a randomized controlled trial. JAMA 285: 2743-2749
13. Schiffmann R et al. (2006) Long-term therapy with agalsidase alfa for Fabry disease: safety and effects on renal function in a home infusion setting. Nephrol Dial Transplant 21: 345-354
14. Schiffmann R et al. (2007) Weekly enzyme replacement therapy may slow decline of renal function in Fabry patients who are on long-term biweekly dosing. J Am Soc Nephrol 18: 1576-1583
15. Ortiz A et al. (2008) Nephropathy in males and females with Fabry disease: cross-sectional description of patients before treatment with enzyme replacement therapy. Nephrol Dial Transplant [doi:10.1093/ndt/gfm848]
16. Brady RO et al. (1971) Fabry's disease: antenatal detection. Science 172: 174-175
17. Vedder AC et al. (2006) Manifestations of Fabry disease in placental tissue. J Inherit Metab Dis 29: 106-111
18. Ries M et al. (2004) Parapelvic kidney cysts: a distinguishing feature with high prevalence in Fabry disease. Kidney Int 66: 978-982
19. Ries M et al. (2003) The early clinical phenotype of Fabry disease: a study on 35 European children and adolescents. Eur J Pediatr 162: 767-772
20. Ries M et al. (2005) Pediatric Fabry disease. Pediatrics 115: e344-e355
21. Gubler MC et al. (1978) Early renal changes in hemizygous and heterozygous patients with Fabry's disease. Kidney Int 13: 223-235
22. MacDermot KD et al. (2001) Natural history of Fabry disease in affected males and obligate carrier females. J Inherit Metab Dis 24 (Suppl 2): 13-14
23. Deegan PB et al. (2006) Natural history of Fabry disease in females in the Fabry Outcome Survey. J Med Genet 43: 347-352
24. Tsakiris D et al. (1996) Report on management of renal failure in Europe, XXVI, 1995. Rare diseases in renal replacement therapy in the ERA-EDTA Registry. Nephrol Dial Transplant 11 (Suppl 7): 4-20
25. Desnick RJ et al. (2003) Fabry disease, an under-recognized multisystemic disorder: expert recommendations for diagnosis, management, and enzyme replacement therapy. Ann Intern Med 138: 338-346
26. Hughes DA et al. (online 1 August 2005) Guidelines for the diagnosis and management of Anderson-Fabry Disease [http://www.dh.gov. uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/ DH_4118404] (accessed 23 October 2007)
27. Clarke LA et al. (online November 2005) Fabry Disease: recommendations for diagnosis, management, and enzyme replacement therapy in Canada [http://www.garrod.ca/data/attachments/CanadianFabryGuidelinesNov05.pdf] (accessed 23 October 2007)
28. Eng CM et al. (2006) Fabry disease: guidelines for the evaluation and management of multi-organ system involvement. Genet Med 8: 539-548
29. Fabry Registry (online 2007) Patient Monitoring [https://www.lsdregistry. net/fabryregistry/hcp/partic/freg_hc_p_monitor.asp] (accessed 23 October 2007)
30. Stevens LA et al. (2006) Assessing kidney function-measured and estimated glomerular filtration rate. N Engl J Med 354: 2473-2483
31. National Kidney Foundation (2002) K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 39 (Suppl 1): S1-S266
32. Kleinert J et al. (2005) Measurement of renal function in patients with Fabry disease. Acta Paediatr Suppl 94: 19-23
33. Alroy J et al. (2002) Renal pathology in Fabry disease. J Am Soc Nephrol 13 (Suppl 2): S134-S138
34. Albay D et al. (2005) Chloroquine-induced lipidosis mimicking Fabry disease. Mod Pathol 18: 733-738
35. Fischer EG et al. (2006) Fabry disease: a morphologic study of 11 cases. Mod Pathol 19: 1295-1301
36. de Zeeuw D et al. (2004) Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL. Kidney Int 65: 2309-2320
37. Kent DM et al. (2007) Progression risk, urinary protein excretion, and treatment effects of Angiotensin-converting enzyme inhibitors in nondiabetic kidney disease. J Am Soc Nephrol 18: 1959-1965
38. Palmer BF (2007) Proteinuria as a therapeutic target in patients with chronic kidney disease. Am J Nephrol 27: 287-293
39. Thurberg BL et al. (2002) Globotriaosylceramide accumulation in the Fabry kidney is cleared from multiple cell types after enzyme replacement therapy. Kidney Int 62: 1933-1946
40. Eng CM et al. (2001) Safety and efficacy of recombinant human alpha-galactosidase A-replacement therapy in Fabry's disease. N Engl J Med 345: 9-16
41. Schwarting A et al. (2006) Enzyme replacement therapy and renal function in 201 patients with Fabry disease. Clin Nephrol 66: 77-84
42. ClinicalTrials.gov (online April 2007) Canadian Fabry Disease Initiative (CFDI) Enzyme Replacement Therapy (ERT) Study (NCT00455104) [http:// clinicaltrials.gov/ct/show/NCT00455104?order=2term=NCT00446862&submit= Search] (accessed 23 October 2007)
43. Vedder AC et al. (2007) Treatment of Fabry disease: outcome of a comparative trial with agalsidase alfa or beta at a dose of 0.2 mg/kg. PLoS ONE 2: e598
44. Warnock DG and West ML (2006) Diagnosis and management of kidney involvement in Fabry disease. Adv Chronic Kidney Dis 13: 138-147
45. Warnock DG (2005) Fabry disease: diagnosis and management, with emphasis on the renal manifestations. Curr Opin Nephrol Hypertens 14: 87-95
46. Beck M et al. (2004) Fabry disease: overall effects of agalsidase alfa treatment. Eur J Clin Invest 34: 838-844
47. Warnock DG (2007) Enzyme replacement therapy and Fabry kidney disease: quo vadis? J Am Soc Nephrol 18: 1368-1370
48. Chobanian AV et al. (2003) The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 289: 2560-2572
49. Kleinert J et al. (2006) Prevalence of uncontrolled hypertension in patients with Fabry disease. Am J Hypertens 19: 782-787
50. Tahir H et al. (2007) Antiproteinuric therapy and Fabry nephropathy: sustained reduction of proteinuria in patients receiving enzyme replacement therapy with agalsidase-beta. J Am Soc Nephrol 18: 2609-2617
51. ClinicalTrials.gov (online 10 April 2007) The Fabrazyme® and Arbs and ACE Inhibitor Treatment (FAACET) Study (NCT00446862) [http://www. clinicaltrials.gov/ct/show/NCT00446862?order=1] (accessed 23 October 2007)
52. Tondel C et al: Glomerular and vascular changes are prominent in renal biopsies in children and adolescents with Fabry disease and minimal albuminuria. Am J Kidney Dis, in press
53. Breunig F et al. (2006) Clinical benefit of enzyme replacement therapy in Fabry disease. Kidney Int 69: 1216-1221
54. Ojo A et al. (2000) Excellent outcome of renal transplantation in patients with Fabry's disease. Transplantation 69: 2337-2339
55. Mignani R et al. (2004) Enzyme replacement therapy with agalsidase beta in kidney transplant patients with Fabry disease: a pilot study. Kidney Int 65: 1381-1385
56. Schiffmann R (2007) Enzyme replacement in Fabry disease: the essence is in the kidney. Ann Intern Med 146: 142-144
57. Fogo A et al. (2006) Developing a chronicity index for kidney involvement in Fabry disease; report of the International Fabry kidney biopsy working group [abstract]. J Am Soc Nephrol 17: 626A
58. Oliveira JP (2007) Staging of Fabry disease using renal biopsies. Clin Ther 29: S15-S16